Skip to main content
Premium Trial:

Request an Annual Quote

Covance, RBM Ink Biomarker Services Pact

NEW YORK (GenomeWeb News) – Drug developer Covance and Rules-Based Medicine have struck a biomarker alliance and services agreement, Covance said today.

Under the pact, RBM will serve as Covance's exclusive third-party provider of multiplexed biomarker testing services, and Covance will serve as RBM's exclusive referral source for lab testing services.

The RBM Multi-Analyte Profiling platform creates efficiency in drug development by providing reproducible, quantitative, multiplexed immunoassay data for hundreds of proteins from small sample volumes, the company said.

"RBM's unique biomarker technology platform, combined with Covance's recent acquisitions and alliances in biomarkers and genomics, strengthens our ability to provide comprehensive biomarker discovery, verification, validation, and deployment in both the preclinical and clinical setting," Covance's Senior VP and President of Central Laboratory Services, Deborah Tanner, said in a statement.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.